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ABSTRACT
Identification of CD8 cytotoxic T lymphocyte (CTL) epitopes has traditionally relied upon testing of overlapping peptide li-
braries for their reactivity with T cells in vitro. Here, we pursued deep ligand sequencing (DLS) as an alternative method of di-
rectly identifying those ligands that are epitopes presented to CTLs by the class I human leukocyte antigens (HLA) of infected
cells. Soluble class I HLA-A*11:01 (sHLA) was gathered fromHIV-1 NL4-3-infected human CD4 SUP-T1 cells. HLA-A*11:01
harvested from infected cells was immunoaffinity purified and acid boiled to release heavy and light chains from peptide ligands
that were then recovered by size-exclusion filtration. The ligands were first fractionated by high-pH high-pressure liquid chro-
matography and then subjected to separation by nano-liquid chromatography (nano-LC)–mass spectrometry (MS) at low pH.
Approximately 10 million ions were selected for sequencing by tandemmass spectrometry (MS/MS). HLA-A*11:01 ligand se-
quences were determined with PEAKS software and confirmed by comparison to spectra generated from synthetic peptides. DLS
identified 42 viral ligands presented by HLA-A*11:01, and 37 of these were previously undetected. These data demonstrate that
(i) HIV-1 Gag and Nef are extensively sampled, (ii) ligand length variants are prevalent, particularly within Gag and Nef hot
spots where ligand sequences overlap, (iii) noncanonical ligands are T cell reactive, and (iv) HIV-1 ligands are derived from de
novo synthesis rather than endocytic sampling. Next-generation immunotherapies must factor these nascent HIV-1 ligand
length variants and the finding that CTL-reactive epitopes may be absent during infection of CD4 T cells into strategies de-
signed to enhance T cell immunity.
IMPORTANCE
HIV-1 epitopes catalogued by the Los Alamos National Laboratory (LANL) have yielded limited success in vaccine trials. Because
the HLA of infected cells have not previously been assessed for HIV-1 ligands, the objective here was to directly characterize the
viral ligands that mark infected cells. Recovery of HLA-presented peptides fromHIV-1-infected CD4 T cells and interrogation
of the peptide cargo by mass spectrometric DLS show that typical and atypical viral ligands are efficiently presented by HLA and
targeted by human CTLs. Nef and Gag ligands dominate the infected cell’s antigenic profile, largely due to extensive ligand sam-
pling from select hot spots within these viral proteins. Also, HIV-1 ligands are often longer than expected, and these length vari-
ants are quite antigenic. These findings emphasize that an HLA-based view of HIV-1 ligand presentation to CTLs provides previ-
ously unrealized information that may enhance the development of immune therapies and vaccines.
The number of individuals infected by HIV-1 continues to in-crease, despite the availability of effective antiviral drug com-
binations and even though the best efforts have been made to
employ traditionally successful as well as novel vaccination strat-
egies. Vaccination strategies use subunit formulations, viral pep-
tides, live attenuated viruses, and DNA-based vectors to deliver
HIV-1 antigens (1). Each approach has generated demonstrable
immune responses to the immunizing antigens, yet notable pro-
phylactic or therapeutic immunity has not arisen. In simian
immunodeficiency virus infection, studies with T cell-eliciting
vaccines have shown results that attribute an important role to
virus-specific T cell responses, even in a preventive vaccine setting
(2–5). Likewise, humanhost determinants that correlatewith pro-
tective immunity in genome-wide association studies consistently
map to the class I loci of the human leukocyte antigens (HLA) on
chromosome 6, further highlighting the crucial role that major
histocompatibility complex (MHC) class I-restricted T cells may
play in containing viral replication. Particular alleles, including
HLA-A*11:01, -B*57:01, and -B27/B*27:05, regularly emerge as
correlates of protection for those exposed to or infected by HIV-1
(6, 7). Theassociationwith lowerviral loadsand longer survival times
supports the premise that particular class I HLA elicit protective an-
tiviral immunity via the selective presentation of HIV-1 ligands.
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Understanding which HIV-1 peptide ligands are presented by
class I HLA-A, -B, and -Cmolecules for T cell recognition is com-
plicated by the outbred nature of human populations, which con-
tain many different HLA allelic combinations and haplotypes. To
come to grips with the breadth and nature of ligands presented for
cytotoxic T lymphocyte (CTL) recognition, peripheral blood
mononuclear cells (PBMCs) from HLA-typed infected individu-
als are generally screened for reactivity to overlapping sets of pep-
tides spanning various retroviral proteins. Gamma interferon
(IFN-) enzyme-linked immunosorbent spot (ELISPOT) and in-
tracellular staining (ICS) assays have now identified hundreds of
CD8 T cell-reactive HIV-1 ligands which are matched to a re-
stricting HLA molecule by algorithm, competitive binding assay,
or traditional HLA restriction analyses. These epitopes are contin-
uously added to the rich compendiumofHIV-1CTL epitopes that
ismaintained by the Los AlamosNational Laboratory (LANL) (8).
This LANL compendium shows that substantial numbers of viral
ligands are targeted by cellular immune responses, and vaccine
architects have used this information to guide vaccine design.
Escape mutations are found in numerous T cell epitopes (9–
12) and are common in those ligands sampled by the highest-
frequency HLA in a particular population or cohort (13, 14).
HIV-1 quasispecies, Nef-mediated inhibition of HLA surface ex-
pression, and viral latency represent additional hurdles for both
natural and vaccine-elicited antiviral immunity in the control of
HIV replication and in providing sterile immunity. Another com-
plicating facet is emerging whereby the viral ligands made avail-
able by the class I molecules of infected cells may differ from those
presented by the class IHLAof antigen-presenting cells (APCs). In
the case of influenza virus, the viral ligands presented by macro-
phage and dendritic cells are not always the same as those pre-
sented by the class I HLA of infected lung cells; an influenza virus
T cell-eliciting vaccine was effective only when it used the epitopes
available on the APCs as well as the infected lung cell (15). Simi-
larly, the class I antigens of infected dendritic cells and epithelial
cells present different length variations of a West Nile virus enve-
lope epitope (16). Together with the recent observation that anti-
gen cross presentation is impaired by Nef (17), these accumulat-
ing data suggest that the class I HLA of HIV-1-infected CD4 T
cells might reveal an as yet unrealized collection of viral epitopes
that are distinct from those epitopes that become apparent in
ELISPOT and ICS assays.
No group has previously reported the elution of HIV-1 ge-
nome-encoded ligands from the HLA of virus-infected CD4 T
cells. In this study, we tested the hypothesis that class I molecules
harvested from HIV-1-infected cells reveal a unique and previ-
ously unverified repertoire of viral ligands marking the infected
cell for immune recognition. HLA-A*11:01 was chosen for study
on the basis of a correlation with longer survival in HIV-infected
patients of European ancestry, an elevated frequency in HIV-ex-
posed but seronegative Thai women, and enrichment in a high-
risk seronegative cohort of men who have sex with men in Am-
sterdam, Netherlands (18–20). Further, considerable numbers of
HLA-A*11:01 CTL epitopes are referenced by LANL (8) for com-
parison to any ligands identified in this study, and HIV-1 ligands
have been crystallized in the context of HLA-A*11:01 (21). More-
over, characterization of a single HLA molecule facilitates an un-
ambiguous assessment of ligand diversity and restriction. In sup-
port of our hypothesis, only 5 of the 42 HIV-1 ligands (12%) that
we identified through deep ligand sequencing (DLS) as being pre-
sented by HLA-A*11:01 have previously been observed. This con-
siderable discovery of previously unreported HLA-A*11:01
epitopes suggests that studies of peptides eluted from the various
HLA of infected cells are poised to reveal an abundant pool of
unrealized viral ligands. It is exciting to investigate the character-
istics of these unappreciated viral ligands and to consider how
these newly discovered epitopesmight be used in a refined vaccine
design that directs T cell immunity toward HIV-1-infected cells.
MATERIALS AND METHODS
Cell lines, transfectants, and virus. SUP-T1 (ATCCCRL-1942) cellswere
cultured in RPMI supplemented with 10% fetal bovine serum. A soluble
HLA-A*11:01 (sHLA) cDNA construct (with a sequence corresponding
to one in which the cytoplasmic and transmembrane domains are re-
moved that also includes a very low density lipoprotein receptor [VLDLr]
purification epitope tag [SVVSTDDDLA]) was cloned into an EcoRI/
HindIII-digested pcDNA 3.1 expression vector (Invitrogen) and then
electroporated into SUP-T1 cells. Transfected cells were cultured and se-
lected in the presence of G418 and subcloned by limiting dilution in 96-
well plates. The sHLA production by the resultant SUP-T1 cell transfec-
tants was measured by sandwich enzyme-linked immunosorbent assay
using both anti-W6/32 and anti-VLDLr monoclonal antibodies (MAbs;
ATCCHB-95 and CRL-2197, respectively) separately as capture antibod-
ies and detected with anti-beta-2-microglobulin (22).
The pNL4-3 construct (catalog number 114, lot number 110199; ob-
tained through the NIH AIDS Reagent Program, Division of AIDS,
NIAID, NIH, from Malcolm Martin) contains full-length, replication-
and infection-competent chimeric HIV-1; the sources of the provirus are
NY5 (5= end) and LAV (3= end) cloned directly from genomic DNA.
OneShot TOP10 chemically competent Escherichia coli cells (Invitrogen)
were used for pNL4-3 propagation. DNAwas purified (PureYield plasmid
maxiprep system; Promega) and then verified for size by EcoRI/BamHI
double restriction digestion. Transfection of HEK293T cells (ATCCCRL-
3216 cells; provided by John T.West) to produce infectious virus particles
was based on a modified version of the Montefiori laboratory protocols.
To determine the tissue culture infectious dose (TCID), virus-containing
culture supernatants were harvested from flasks at 48 h posttransfection
and titrated in 96-well plates in quadruplicate using cells of the TZM-bl
cell line (a CD4 long terminal repeat/-galactosidase [-Gal] indicator
cell line; catalog number 8129, lot number 110134; obtained through the
NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH, from John
C. Kappes, XiaoyunWu, and Tranzyme, Inc.). After 48 h, the viral super-
natant was removed; and infected cells were fixed, then incubated over-
night with X-Gal (5-bromo-4-chloro-3-indolyl--D-galactopyranoside;
-Gal staining kit; catalog number K1465-01; Invitrogen), and examined
by light microscopy for colorimetric identification of infected cells. The
number of infectious units per milliliter was then determined as previ-
ously described (23).
SUP-T1 cell bioreactor infection, monitoring, and flow cytometry.
The SUP-T1 HLA-A*11:01 transfectant was expanded in culture in a
CP2500 hollow-fiber bioreactor (Biovest International) and monitored
daily for glucose consumption, pH, and sHLA production. Viral superna-
tant containing infectious particles was injected directly into the bioreac-
tors via the feeding container daily. At 24 h postinfection and daily there-
after, the titer in the supernatant recovered from the bioreactor was
determined as described above to track the viral load and confirm a stable
infection. The percentage of cells infected with HIV-1NL4-3 was alsomon-
itored daily by intracellular staining (cell fixation and cell permeabiliza-
tion kit; catalog number GAS004; Life Technologies) with Alexa 647
(MAb labeling kit, catalog number A20186; Invitrogen)-conjugated anti-
HIV-1 p17 (clone 2D11; Abcam) and phycoerythrin-conjugated anti-
HIV-1 core antigen (which recognizes theGag p55 polyprotein precursor,
p39 and p33 intermediate products, and p24 core protein; clone KC57;
Beckman Coulter). Flow cytometric data were collected on an S1200Ex
HLA-Presented HIV-1 CTL Epitopes
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flow cytometer (Stratedigm) and analyzed using FlowJo software (Tree
Star, Inc.).
Isolation and analysis of peptide ligands. The sHLA-peptide com-
plex was affinity purified from cell supernatant on an anti-VLDLr Sephar-
ose column. Peptide was released from class I heavy and light chains by a
10% acetic acid boil (78°C), pooled, and then passed through a stirred cell
ultrafiltration device (3-kDa-cutoff membrane [Millipore]). Efficient
separation and sequencing of directly eluted ligands were carried out by
two-dimensional nano-liquid chromatography (nano-LC)-mass spec-
trometry (MS), followed by information-dependent acquisition (IDA)-
generated tandem MS (MS/MS) (Fig. 1). For the first dimension, the
peptides were loaded on a reverse-phase column (pore size, 90 Å; 2 mm
[inside diameter {i.d.}] by 150 mm long; Jupiter 4 m Proteo; Phenom-
onex) with a Michrom Paradigm MG4 high-pressure liquid chromato-
graph (HPLC). Elution was under high-pH (pH 10) conditions with 2 to
10% acetonitrile in a water gradient for 2 min and then 10 to 60% aceto-
nitrile in water gradient for 60min. Thirty-six peptide-rich fractions were
collected along the gradient and dried by vacuum centrifugation.
Each dried fraction was resuspended in 10% acetic acid and placed
into the autosampler of an Eksigent nanoLC400 U-HPLC system (AB
Sciex). Twenty percent of each fractionwas sequentially run through a pH
2-equilibrated, reverse-phase nano-HPLC column. The second-dimen-
sion nano-HPLC setup includes a C18 trap column (350 m (i.d.) by 0.5
mm long; ChromXP) with 3-m particles and 120-Å pores and a
ChromXP C18 separation column with dimensions of 75 m (i.d.) by 15
cm long packed with the same medium. A two-solvent system was uti-
lized, where solvent A is 0.1% formic acid in 98% water and 2% acetoni-
trile and solvent B contains 0.1% formic acid in 5% water and 95% ace-
tonitrile. Samples were loaded on the trap column at a 5-l/min flow rate
and the separation column at a 300-nl/min flow rate following a program
with two linear gradients: 10% to 40% solvent B for 70min and then 40 to
80% solvent A for 10 min. The second-dimension HPLC column effluent
was connected to the nanospray III ion source of an AB Sciex 5600 qua-
drupole-time of flight mass spectrometer.
Analysis and validation of mass spectrometry data. The 36 first-di-
mension fractions generated 425,973 LC-MSmaps, with the correspond-
FIG 1 Deep ligand sequencing and validation of peptide ligands recovered from class I HLA of HIV-1-infected CD4 T cells. (A) Deep ligand sequencing work
flowwhereby SUP-T1CD4Tcells are infectedwithHIV-1NL4-3. SolubleHLA is purified by immunoaffinity chromatography, andHLA is separated frombound
peptides by acid boil and size exclusion filtration (3-kDa cutoff). Directly eluted peptides are then fractionated at high pH. mAU, milli-absorbance units;
RP-HPLC, reverse-phase high-pressure liquid chromatography. (B) Fractions are further separated at low pH and directly injected into an AB Sciex 5600 mass
spectrometer to generate LC-MS spectra and corresponding information dependent acquisition (IDA)-generated MS/MS spectra. PEAKS software, using a 1%
false discovery rate, assigns the ligand sequence for synthesis. (C) Finally, ligands undergo a three-step validation process to include comparison of synthetic
MS/MS spectra, IC50 determination by competitive binding assay, and the extent of T cell reactivity by ELISPOT assay testing against patient PBMCs.
Yaciuk et al.
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ing MS/MS fragmentations totaling 9,371,406. MS/MS fragmentation
spectra were processed using a multilayered, complementary application
of PEAKS (Bioinformatic Solutions) algorithms. All sequence assign-
ments were made following a 1% false discovery rate and were within 50
ppm of the theoretical mass. Variable modifications, such as N-terminal
acetylation, deamidation (asparagine and glutamine), oxidation (histi-
dine, tryptophan, and methionine), and the presence of sodium adducts
(aspartic or glutamic acid and C terminal) and the pyroglutamate deriv-
ative of glutamic acid, were also considered. All HIV-1 sequence assign-
ments were confirmed by comparison to synthetic MS/MS spectra; vali-
dation requirements included MS/MS spectrum and LC retention time
(within 5 min) matches.
Peptide binding inhibition assay.The recovered ligands were further
confirmed for HLA-A*11:01 binding via a competitive peptide binding
inhibition assay as measured by fluorescence polarization (Pure Protein,
LLC) (24–26). For the binding assay, the peptides of interest compete for
binding to sHLA-A*11:01 against a standardized fluorescein isothiocya-
nate (FITC)-labeled control peptide used as a tracer. The binding affinity
for each peptide is calculated as the concentration (nM) that inhibits 50%
binding of the FITC-labeled reference peptide (IC50) by measuring the
fluorescence polarization (FP) at titrated dilutions and at set time points
and then at the same time points 24 and 48 h after assay initiation to assess
stability.Maximal FP values are then plotted as a function of the logarithm
of the concentration of the peptide of interest. The binding affinity for
HLA-A*11:01 was as follows: high binders, IC50s of less than 5,000 nM;
medium binders, IC50s of 50,000 nM; low binders, IC50s of 350,000
nM; and very low binders, IC50s of 1  10
6 nM. Any peptide with an
IC50 of greater than 1 10
6 nM was designated a nonbinder and given a
score of 0.
ELISPOT assay testing for CTL reactivity to HIV-1 ligands. T cell
reactivity to synthetic peptides representing both LANL-reported HIV-1
epitopes and ligands discovered from infected CD4 T cells by direct
discovery was tested. IFN- ELISPOT assays were performed using cryo-
preserved PBMCs. The PBMCs tested were derived from a total of 23
HLA-A*11:01-positive, HIV-1-infected adults, including elite controllers
(who have not received combination antiretroviral therapy [cART] and in
whomHIV-1 is undetectable, allowing nonconsecutive blips in20% of
samples; n 	 3), viremic controllers (who have not received cART and
who have sustained viral loads of 2,000 copies/ml; n 	 5), untreated
individuals with chronic HIV infection (individuals with HIV infection
who have not been treated or who are naive to or who have previously
received antiretroviral therapy [ART]; n 	 5), and ART-treated patients
(n	 10), as well as 3 seronegative controls. Viral loads were determined
using the Roche Amplicor (version 1.5) assay; CD4 T cell counts were
determined by flow cytometry. Using previously established criteria (27),
a response was considered positive when it exceeded at least 5 spots per
well (50 spot-forming units [SFU]/106 PBMCs), when it exceeded the
mean plus 3 standard deviations for negative-control wells, and when it
exceeded three times the mean number of spots in the negative-control
(unstimulated) wells. The human subjects aspect of this study was ap-
proved by the Ethical Committee of Clinical Investigation (reference
CEIC, PI-13-017) at the Germans Trias i Pujol Hospital as well as by the
Institutional Review Board (IRB) at the University of Oklahoma Health
Sciences Center (IRB approval number 3397).
RESULTS
Ligand recovery and de novo discovery. Since CD4 T cells are
the primary target of HIV-1, we infected a CD4 T cell line, SUP-
T1, with HIV-1NL4-3 in order to isolate and characterize naturally
processed and endogenously loaded viral epitopes. To simplify
isolation of ligands and focus on those presented by a critical HLA
allele, cells of the SUP-T1 cell line were transfected with a VLDLr-
tagged, soluble HLA-A*11:01 construct. Soluble HLA has been
demonstrated to traffic normally through the cell (28), and the
sHLA gathered from infected cells is obtained at a high yield in a
very clean format. Other methods used for the recovery and anal-
ysis of HLA-loaded and presented peptide ligands, such as those
utilizing cells lysed by detergents, contain complex protein mix-
tures, including multiple HLA alleles. The infection status of the
cells in the bioreactor was determined daily by intracellular p24
staining and flow cytometry (data not shown). HLA-A*11:01
complexes secreted into the supernatantwere immunoaffinity pu-
rified, and peptides were acid eluted from the class I molecule,
separated from HLA heavy and light chains by size-exclusion fil-
tration, and submitted for DLS (Fig. 1A).
Thirty-six peptide-containing high-pH HPLC fractions were
subsequently subjected to separation by LC-MS at low pH, and
approximately 107 ions were selected for sequencing by tandem
mass spectrometry (Fig. 1B). Nearly 20,000 nonredundant, high-
quality MS/MS spectra were derived (data not shown), and from
these MS/MS spectra, 8,497 high-confidence Homo sapiens host
peptide sequences were identified (data not shown), as were 42
high-confidence HIV-1NL4-3 peptide sequences derived from five
HIV proteins: Nef, Gag, Pol, Env, and Vpu (Table 1). Four HIV-1
ligands contained naturally occurring amino acid mutations that
differed from the input HIV-1NL4-3 sequence. Synthetic peptides
matching each HIV-1 ligand were subjected to the same MS/MS
collision conditions; fragmentation patterns (data not shown)
were subsequently compared and confirmed all 42 HIV-1 ligand
sequence assignments. Example DLS data for the HLA-A*11:01
ligand Nef-AK10, found here and previously reported in the
LANL database, are shown in Fig. 1B and C. Once the amino acid
sequences of all HIV-1-derived ligands discovered de novo were
validated byMS/MS comparison to synthetic peptide controls, the
synthetic peptides were subjected to an in vitro binding competi-
tion assay (24–26) to determine their binding affinity for HLA-
A*11:01 (Table 1).
Of the 42 HIV-1 ligands listed in Table 1, 9 from Gag and Nef
showed reduced binding stability over time, meaning that the
FITC-labeled peptide control eventually outcompeted the HIV-1
peptide for binding to sHLA (where bindingwas initially observed
as a decrease in the FP level, which then returned to a level nearly
equivalent to the FP level observed for the FITC-labeled peptide
only in the presence of sHLA). Two of these unstable ligands from
Gag were medium binders, and the others were designated low/
very lowbinders.Nevertheless, a 14-mer and a 17-mermaintained
stable binding to HLA-A*11:01, and a 17-mer from Nef also
bound, while the Gag 20-mer complex was unstable because over
time it disassociated fromHLA-A*11:01. Further, three Gag non-
binders did not fit the expected motif in their C-terminal (P
)
anchor. Three Pol ligands fromp51 reverse transcriptase (RT) and
p31 integrase (Int) were high binders, while two additional Int
ligands did not bind, even though there appeared to be nothing
unusual about their motif. Oddly, for two overlapping ligands
from Int, a 16-mer and a 13-mer with the same C-terminal an-
chor, the longer ligand bound with a high affinity, while the
shorter ligand showed no binding. The Env and Vpu ligands were
high binders. Clearly, many longer, noncanonical peptides that
are directly eluted from HLA-A*11:01 bind with appreciable af-
finity.
Of the 42 HIV-1 ligands identified in this study, 5 have been
previously reported in the LANL HIV Molecular Immunology
Database. Many of the ligands identified here came from hot
spots, or overlapping clusters of HIV-1 ligands (Table 1; Fig. 2).
More than half (n	 24) arose fromHIV-1Gag, with ligands being
HLA-Presented HIV-1 CTL Epitopes
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dispersed throughout the viral protein. The next-richest source of
ligands was Nef, which provided 11 peptide ligands, predomi-
nantly from the N-terminal half of this protein. Five epitopes that
were fairly evenly, albeit sparsely, dispersed throughout the poly-
merase protein were recovered from HLA-A*11:01, while Vpu
and Env were sampled only once. DLS therefore reveals a large
number of previously unrealized viral ligands, as well as a few
(Gag-SIK10; Nef-QK10, -AK10, and -AK9; and Pol-QK11) previ-
ously reported ligands (Table 1).
Several known HLA-A*11:01 HIV-1 epitopes are not pre-
sented.Wewere concerned that theHIV-1 ligands reported in the
LANL database but not found here may have been overlooked or
underrepresented by our DLS approach. We therefore searched
specifically for the predicted masses of these missing ligands
among all the LC-MS/MS data that we had recorded. The ligands
that we searched for included 12 well-characterized, HLA-A*11:
01-associated ligands found in the LANL HIV Molecular Immu-
nology Database that match the HIVNL4-3 sequence: Gag-AK11,
-TK12, and -EK15; Gag-pol/protease-VK10; Nef-PK8; RT-IK10,
-FK9, and -QK9; Int-AK10; Pol-IK9; andEnv-VK11 and -SK9.We
additionally searched the DLS data for 3 previously reported
HIV-1 ligands that include the Gag-AK11mutant with the G225S
mutation and two ligands modified by 1 to 2 internal amino acids
to match HIVNL4-3 (Gag-IR10 and RT-AK9). Nef-SR9 (SVIGWP
AVR) was also included in our retrospective search because it is
presumed to be a better binder than Nef-SR11 (SVIGWPAVRER,
where the boldface amino acids emphasize the two-amino-acid
C-terminal extension not present in Nef-SR9) as well as the two
TABLE 1 Candidate ligands recovered and validated from HLA-A*11:01 of HIV-1-infected CD4 T cellsa
a NL4-3 mutation variants are designated with bold underlining. The binding affinity for HLA-A*11:01 was as follows: high binders, IC50s of less than 5,000 nM; medium binders,
IC50s of50,000 nM; low binders, IC50s of350,000 nM; very low binders, IC50s of1 10
6 nM. Any peptide with an IC50 of greater than 1 10
6 nM was designated a
nonbinder and given a score of 0. Max, maximum.
Yaciuk et al.
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shorter versions, IR9 and GR8, found by DLS. Although Nef-SR9
is included in the LANL database, it was not reported for HLA-
A*11:01 but, rather, was associated with another allele, HLA-
A*03:01. So, it is intriguing that this LANL sequence, while absent
in this study, happens to be the core of 3 DLS HLA-A*11:01 li-
gands.
Overall, a top-down de novo search of theDLSdata for peptides
whose masses matched the masses of previously reported ligands
did not lead to the identification of the missing ligands. Next, a
bottom-up approach processed synthetic peptides for each of
these reported ligands through theDLS system. Searching theDLS
data using the synthetic peptides’ low-pH retention time and MS
ion mass, we were unable to detect these missing ligands. Again,
searching the DLS data, but this time using the synthetic peptides’
MS/MS fragmentation patterns as a search parameter, we were
again unable to detect the missing ligands. Thus, using synthetic
peptides as a guide for searching the DLS ligands of HIV-1-in-
fected cells, we were still unable to identify 16 missing peptide
ligands that fit the HIVNL4-3 sequence and that have previously
been reported to be viral epitopes.
Comparisonofhost-derived andHIV-1-derived ligands.The
characterization of 8,497 host- and 42 HIV-1-derived ligands
eluted from the HLA of infected cells provides an unprecedented
view of the retrovirus-infected cell’s ligand repertoire. We used
this unique resource to assess and compare the ligands presented
by the HLA-A*11:01 of infected cells with respect to three differ-
ent parameters: sequence motif, ligand length, and source protein
sampling frequency. Within the host ligands recovered from
HIVNL4-3-infected cells, we determined a motif (Fig. 3A, top) that
is expected for HLA-A*11:01 (21). At the P2 anchor position, we
observed a dominant threonine (T) and valine (V) with a sub-
dominant isoleucine (I), leucine (L), and serine (S). For the C-ter-
minal anchor position (also commonly referred to as the P
 po-
sition), we observed lysine (K), accounting for 84% of the ligands,
with a subdominant arginine (R) accounting for 9%of the ligands.
We also noted a strong preference for small amino acids (S, ala-
nine [A], V, T, and glycine [G]) at P1 as well as an L preference at
the P
-1 position. TheHIV-1-derived ligands coincided with this
motif (Fig. 3A, bottom), although there were distinct biases at the
P1, P2, and P
 positions of the viral ligands that differed from the
sequence of the host-derived ligand motif (Fig. 3A, top). With
respect to P1, HIV-1 ligands preferred an S but shifted away from
A as a secondary preference toward a T compared with the host
ligand sequences. At P2, V was preferred, but T was diminished in
the HIV-1 ligands and subordinate residues glutamine (Q) and G
were elevated. At P
, HIV-1 ligands preferred K but were skewed
substantially toward R compared to the sequences of the host li-
gands. Overall, the HIV-1 ligands fit the parameters of the HLA-
A*11:01 motif, yet the HIV-1 ligands showed shifts within this
motif.
Ligands were next comparatively analyzed by length. Among
the host-derived ligands, we saw a distribution whereby ligands
that were 9 to 11 amino acids (aa) predominated. Nevertheless,
the breadth and quantity of longer ligands made apparent by DLS
are striking (Fig. 3B); peptides of 11 to 42 amino acids in length
accounted for 43% of the total recovered. HIV-1-derived ligands
fell within this distribution, whereby a majority of ligands were of
canonical length and where longer ligands were also detected.
These data show that virus-derived epitopes and HLA-A*11:01
host ligands have a similar length distribution and that a number
FIG 2 Sequence alignment of HIV-1 ligands recovered from the HLA of infected CD4 T cells. A total of 42 ligands sampled from 5 HIV-1 proteins were
recovered from HLA-A*11:01 of infected SUP-T1 CD4 T cells. (A) The location of each ligand is shown for each source protein. The 42 ligands included 5 (1
Gag, 3 Nef, and 1 Pol, all indicated in green) previously reported LANL epitopes. Four additional unique ligands were processed from Pol, and one each was
processed from Vpu and Env. Four Gag ligands (all of which span proteolytic cleavage sites, designated in red) contain point mutations from the native
HIV-1NL4-3 sequence. Seventeen ligands, including 2 of the mutant sequences (bold and underlined) and 2 of the LANL epitopes, represent multiple length
variants and overlapping sequences from hot spots within Nef and Gag. (B) The Gag hot spot sequence from amino acids 361 to 384 is shown, with Gag
polyprotein cleavage points indicated by arrows. Gag cleavage gives rise to mature p24, p2, and nucleocapsid (NC) proteins. Ten of the 12 overlapping
HLA-A*11:01-associated Gag ligands (indicated in red) are predominantly derived from immature virus since they span these cleavage points. Two ligands (in
blue) from the Gag p2 protein that have noncanonical C-terminal anchors for HLA-A*11:01 fall between these two cleavage sites.
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of viral epitopes exceed previously reported HIV-1 epitope length
parameters.
Finally, HIV-1- and host-derived HLA-A*11:01 ligands were
stratified according to the number of times that a particular pro-
tein was sampled. For host ligands, a trend emerged whereby sin-
gle ligands were sampled from approximately a third of the host
proteins represented, 2 peptides from roughly 20% of the host
proteins were sampled by HLA-A*11:01, and a minority of pro-
teinswere sampled several times; 125 EEF1A ligandswere sampled
(Fig. 3C). In comparison, the sampling of peptides from HIV-1
proteins is skewed toward the higher end of the spectrum,
whereby 24 ligands were found from Gag, 11 were found from
Nef, and 5were found fromPol. This degree of increased sampling
is consistent with the abundant expression and cytoplasmic local-
ization of Gag/Gag-Pol and Nef in infected cells. Only Env and
Vpu protein sampling was in line with that seen for host source
proteins (Fig. 3C). This is perhaps not surprising, since both Env
and Vpu proteins are membrane associated and Env is predomi-
nantly localized in the secretory pathway lumen. In summary,
HIV-1 ligands fit within themotif and length distribution seen for
host ligands, albeit there are some shifts in anchors and some
longer sequences for HIV-1 ligands, and more peptide ligands
tend to be sampled per individual HIV-1 protein than the number
sampled from host proteins by the use of HLA-A*11:01.
De novo-discovered ligands from infected cells bind HLA
and are T cell reactive. To determine the T cell reactivity of the 42
HIV-1 ligands found by DLS, synthetic peptides were used to
stimulate PBMCs from HLA-A*11:01-positive HIV-1-infected
individuals (n 	 23) and seronegative HLA-A*11:01 control pa-
tients (n 	 3) in a gamma interferon ELISPOT assay. No HIV-1
ligands elicited responses in control patients (data not shown).
Three ligands, Nef-QK10, Nef-VK17, and Pol-QK11, induced the
highest median-magnitude (i.e., strength) responses (Fig. 4A) in
the largest number of responding patients (i.e., frequency; Fig.
4B). The largest number of patients (n 	 19) responded to Nef-
QK10, a well-described LANL epitope that we also identified by
DLS, and this ligandwas associatedwith the third highestmedian-
magnitude response. Furthermore, Pol-QK11 is a high-affinity
binder, had the highestmedian strength of response, andwas third
highest in terms of the number of patients responding (n	 15 of
23). The ligands Nef-QK10, Nef-VK17, and Pol-QK11 were most
reactive in regard to the strength and the frequency of the re-
sponse.
Figure 4A also demonstrates a wide range of responses for the
identified ligands, including the 3 dominating ligands from Nef
and Pol, where several patients showed responses greater than
3,000 SFU/106 PBMCs compared to the highest median response
of 920 SFU/106 cells for Pol-QK11. Seven of 11 Nef ligands
FIG 3 Source protein amino acid sequence motif, length distribution, and sampling frequency of ligands recovered fromHLA of HIV-1-infected CD4 T cells.
(A) Analysis of the 8,497 total host-derived and 42 HIV-derived ligands discovered de novo from HIV-1-infected cells by DLS shows the amino acid sequence
motif for peptide ligands recovered from HLA-A*11:01, where lysine (K) overwhelmingly dominates the C-terminal P
 position in host-derived and HIV-
derived ligands and where an increase is also seen for arginine (R) in HIV-1-derived peptide ligands. Distinct variations and preferences at N-terminal anchors
and internal sequence patterns for HIV-1-derived versus host-derived ligands are apparent. (B) Peptide ligands from both the host and HIV-1 demonstrate the
expected canonical length of 9 to 11 amino acids for class I HLA. (C) Finally, the source protein ligand sampling frequency was greater for HIV-1-derived ligands
than host-derived ligands. N-Term and C-Term, N and C termini, respectively.
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(63.6%) and 2 of 5 Pol ligands (40%) had a median response of
300 SFU/106 cells (the top one-third of all identified ligands
responded at this level or higher), whereas 5 of 24 Gag ligands
(20.8%) had a median response of 300 SFU/106 cells. The me-
dian response for Env-RR11 was 365 SFU/106 cells, while that for
Vpu-RR9 was 125 SFU/106 cells. With respect to the number of
responders shown in Fig. 4B, 5 of 24 Gag ligands (20.8%) were
seen by the CTLs of 10 or more patients (20%), while the same
can be said for 5 of 11 Nef ligands (45.5%) and 2 of 5 Pol ligands
(40%), further emphasizing the potential significance of Nef and
Pol as sources of a maximal immune response.
Since 15 out of 23 patients (65%) responded to themost C-ter-
minal hot spot Nef ligands, the IC50 values (Fig. 5A) for these
overlapping peptides (Table 1; Fig. 2) were specifically measured
and calculated to identify a potential correlation between binding
affinity and T cell reactivity (Fig. 5B). The longest ligand, KK11,
had the highest binding affinity (IC50 	 150 nM, or log IC50 	
2.178), AK9 and AK10 were high binders (IC50s	 225.2 nM [log
IC50	 2.353] and 330.9 [log IC50	 2.520], respectively), andVK8
and DK7 bound less efficiently (IC50s 	 18,805 nM [log IC50 	
4.274] and 46,686 [log IC50	 4.669], respectively). PBMCs from
14 of 15 HIV-1-infected individuals responded to the longest Nef
ligand, KK11, with 300 SFU/106 PBMCs (the cutoff described
previously for the top one-third of responses) being found in 8 of
those patients (almost 60%). On the other hand, only 7 of 15
HIV-1-infected individuals respond to the shortest peptide, DK7,
and only 1 of those responders yielded a response of 300 SFU/
106 PBMCs. Overall analysis of ligands in this hot spot revealed a
FIG4 Functional testing of the discovered ligands againstHIV-1-infected patient PBMCsbyELISPOTassay. Synthetic peptides for both the detected ligands and
the LANL-reported epitopes were tested for their ability to stimulate HLA-A*11:01, HIV-1-infected patient PBMCs (n	 23), as measured by IFN- production
via ELISPOT assay. PBMCs from seronegative patients (n	 3; not shown) were tested to control for background. (A) CTL reactivity is indicated by the median
magnitude of IFN- production according to the number of SFU/106 PBMCs for each ligand by increasingmedian response along the x axis. Each dot per ligand
represents the response of an individual patient. Hash marks indicate the median response, and vertical bars represent the interquartile range per ligand. (B)
Frequency of response or number of responders per ligand. Ligands are listed along the x axis in the same increasingmedian-magnitude order as in panel A. Note
that the 3 ligands with the highest frequency (2 fromNef and 1 from Pol) were also the three with the highest median response. An ELISPOT assay response was
considered positive when it exceeded at least 5 spots per well (50 SFU/106 PBMC), when it exceeded themean plus 3 standard deviations for the negative-control
wells, and when it exceeded three times the mean number of spots in the negative (unstimulated) control wells. m, mutant of native HIV NL4-3 sequence.
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response preference for the longer ligands on the basis of binding
affinity, the number of responders, and themedian strength of the
response. It is interesting to note that only 1 of the 15Nef respond-
ers did not react to KK11, and 2 patients responded only to KK11
and no other ligand in that overlapping region.
Adisconnect betweenbinding affinity and immunogenicity for
the ligands within the Gag hot spot emerged, and pinpointing the
traits that mark an optimal epitope is complicated because these
ligands have noncanonical lengths, unusual anchors, and muta-
tions. To begin, SQK13, QK12, VK11, and TK10were stableHLA-
A*11:01 high binders that yielded a relatively lowCTL response in
few infected individuals (Table 1; Fig. 4B). The ligand TK10 was a
high, stable binder with a typical length and anchors, yet it was
immunologically inert, while its mutants, TLK10 andMK10, were
immunogenic, albeit with a low patient responsiveness and fre-
quency (Table 1; Fig. 5C). Paradoxically, the AR11, TR10, and IR9
ligands at the C terminus of this Gag hot spot bound poorly to
HLA-A*11:01, yet they had a considerable median response in
FIG 5 Binding affinity and ELISPOT assay reactivity of 5 Nef hot spot ligands. PBMCs from 23 HLA-A*11:01, HIV-1-infected patients were tested by ELISPOT
assay for reactivity toHIV-1-derived ligands recovered from theHLAs of infected cells. (A) The data compare the binding affinity (IC50, nM) of eachNef hot spot
ligand. (B) The data demonstrate that 15 of 23 patients responded to at least 1 of the 5 overlapping Nef hot spot ligands. Filled circles, a response with a mean
magnitude of300 SFU permillion cells; open circles, a patient response of300 SFU permillion cells. The cutoff of 300 SFU permillion cells was selected since
the top one-third of all ligands recovered from infected cells responded at this level or higher. (C) For reference, a heat map demonstrating all 23 patients’ HIV-1
status and breadth of response to each of the 42 ligands is shown. The 5 ligands recovered from the HLA of infected cells that are also reported by LANL to be
HLA-A*11:01-associated CTL epitopes are highlighted in green.
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several individuals. Most surprising was the finding that the three
longest ligands at the N terminus of the hot spot, RK20, AM14,
and SQK13, all bound with appreciable affinity and elicited con-
siderable CTL responses (Table 1). These inconsistent values
within a cluster of overlapping Gag ligands show that binding
affinity, length, or canonical anchors are not always indicative of
immune reactivity. The breadth of the response of the 23 individ-
ual patients (and their correspondingHIV status) to each of the 42
ligands nonetheless confirms that longer ligands, poor binders,
andmutants are reactive inmultiple individuals of different infec-
tion status (Fig. 5C).
Sequence alignment and properties of HLA ligands from in-
fected cells.Previously reported LANLHLA-A*11:01 viral ligands
originate from 4 HIV-1 proteins, Gag, Nef, Pol, and Env, and we
detected ligands from the same 4 proteins plus an additional novel
ligand derived from the accessory protein Vpu. Sequence align-
ment of all ligands within their respective viral source protein
revealedmultiple length variants localized to hot spots within Nef
and Gag (Table 1; Fig. 2). Two of five Pol ligands were also over-
lapping. The 24 ligands from Gag were dispersed throughout this
500-amino-acid polyprotein, with 12 ligands being derived from a
24-amino-acid (aa 361 to 384) hot spot containing the core se-
quence SQVTNPATIM.These ligands overlay theGag p24-p2 and
Gag p2-nucleocapsid (p7NC) cleavage sites (Table 1; Fig. 2B), and
although these overlapping ligands share much of their core se-
quence, they differ in their binding affinity and ELISPOT assay
response patterns (Fig. 5C). This observation again reiterates that
closely related hot spot ligands can vary inHLA binding and T cell
reactivity.
Four ligands, all from Gag from the native HIV-1NL4-3 se-
quence, included point mutations (Table 1), and these toggling
substitutionsmight represent an adaptation of HIV-1 to the high-
density culture conditions of the hollow-fiber bioreactor. TLK10
and MK10 from within the hot spot have been described earlier
with respect to binding and reactivity. The twoothermutants, SK9
and SR9, also overlapped a longer variant, TR12; these three li-
gands span amino acids 122 to 137, which overlays the matrix
(MA)-p24 cleavage site between the tyrosine (Y) and proline (P)
of these ligands. Ligands SK9 and SR9 are toggling mutants, dif-
fering from HIV-1NL4-3 in their C-terminal anchor, where this
position at aa 137 is an asparagine (N) in the native sequence.
Since K or R is the preferred amino acid at the P
 position for the
HLA-A*11:01motif and the P
 position is critical for binding for
this HLA allele, it is not surprising that a ligand matching the
native sequence was not recovered.
Of the 11 Nef ligands, 5 overlapping ligands are localized to
a hot spot. SR11, the longest of 3 additional overlapping ligands
spanning amino acids 9 to 19, yielded the best HLA-A*11:01
binding of the 3, while IR9 and GR8 were poor, unstable bind-
ers, despite yielding CTL reactivity (Table 1; Fig. 4). Ligands
sampled from HIV-1 polymerase were found in the C-terminal
half of the 1,003-amino-acid protein spanning p51 RT (includ-
ing the dominant ligand based on ELISPOT assay reactivity and
response frequency) and p31 integrase. Finally, the ligand from
Vpu is internally located in this relatively short accessory pro-
tein (81 amino acids), and the single ligand derived from the
HIV-1 envelope is in the very C-terminal part of this protein
beginning at aa 826.
DISCUSSION
For more than 3 decades, HIV-1 infections have led to consider-
able morbidity and mortality in the human population. During
this time, efforts to identify correlates of immune protection have
yielded a number of critical observations. From a humoral per-
spective, the characterization of broadly neutralizing antibodies
and the plasma cells that secrete these antibodies suggests that
specific routes of B cell immune maturation are key to eliciting
protective immunity (29–32). From a T cell perspective, the pre-
sentation of viral peptide ligands by particular HLAmolecules, in
conjunction with specific T cell receptor usage, correlates with
protection from both infection and disease progression (33). As
research progresses, findings continue to enhance our under-
standing of how the adaptive immune response targets virus-in-
fected cells. Recent observations suggest that the HLA of profes-
sional APCs present a set of viral ligands that overlaps with, but is
not necessarily identical to, the viral ligands presented by the class
I HLA of cells in the periphery. Hoping to provide a new series of
T cell targets for testing by vaccine architects, the objective of this
study was to use class I HLA gathered directly from virus-infected,
CD4 T cells as the starting point for discovering HIV-1 CTL
epitopes. The resulting data provide a contemporary set of HIV-
1-derived ligands that are made available to CTLs.
Deep ligand sequencing (DLS) is an approach whereby tens of
thousands of endogenously and naturally loaded peptide ligands
are first harvested from a given class I HLA molecule and then
sequenced at high confidence. A look at the ligands sampled dur-
ing infection shows that the vast majority of ligands recovered are
nonamers with canonical P2 and P9 anchors. However, due to the
shear number of peptides processed, DLS reveals previously un-
reported nuances in ligand presentation, which includes the ob-
servation that hundreds of peptides 20 amino acids or more in
length are sampled from host proteins and presented by class I
HLAmolecules. This observation holds true for theHIV-1 ligands
aswell. In fact, Gag epitopes as long as 20 amino acids (RK20)were
eluted fromHLA-A*11:01, found to bindHLA-A*11:01 in a com-
petitive binding assay, and recognized by T cells in an ELISPOT
assay. Shorter peptides, such as Nef-DK7, were likewise eluted,
recognized by CTLs, and found to bind HLA-A*11:01. Nef-DK7
activity is likely due to a preference for an aspartic acid (D) at P4 in
the DLS motif for HLA-A*11:01. Despite an initial suspicion that
AM14 and SM10 also may not bind HLA-A*11:01, the extensive
motif established here shows that alanine (A) and serine (S) are
elevated at P1 14% and 21%, respectively. DLS analysis elucidates
that HIV-1 ligands that are noncanonical in sequence and in
length are made available to T cells by the class I HLA of infected
cells.
Given the tremendous scope of peptides that DLS provides for
subsequent analysis, we begin to understand how HLAmolecules
sample the individual proteins within an infected cell. Here, pep-
tide constituents from 1,629 different host proteins and 5 viral
proteins were sampled by HLA-A*11:01. As illustrated in Fig. 3C,
a third of the host proteins had only a single ligand harvested for
presentation by HLA-A*11:01, providing a Gaussian distribution
whereby only a few of the cell’s proteins were sampled for several
peptides. At the far end of the spectrum, host proteins such as
tubulin were sampled for 59 overlapping length variants within a
65-amino-acid stretch (data not shown).While a discussion of the
host ligands presented by class I HLA during HIV-1 infection is
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beyond the scope of this study, a similar pattern of multiple over-
lapping peptides being sampled from HIV-1 Gag and Nef was
observed (Fig. 2). These HIV-1 epitope length variants were pre-
dominantly right justified to the dominant arginine (R)/lysine (K)
C-terminal anchor, suggesting that longer HIV-1 peptides were
solidly anchored at their C termini and either bulging in the mid-
dle of the peptide binding cleft or, in the case of Gag-RK20, po-
tentially extending outside the groove at the N terminus of the
ligand. As proteomic methods become more advanced, accumu-
lating data support the observation that longer peptides are being
presented by class I HLA molecules, and the suggestion that we
sometimes cut ourselves too short in mapping CTL epitopes is
evidenced here (8, 34–36). Perhaps future endeavors that focus on
these overlapping clusters will elucidate whether these epitope hot
spots are immunologically neutral, represent yet anothermeans of
HIV-1 escape from the selective pressure of T cell immunity, or
represent an immunologic HLA-A*11:01 advantage by diversify-
ing T cell targets within a selected region of HIV-1.
The ligands characterized in this study were eluted directly
from immunoaffinity-purified HLA-A*11:01, were predomi-
nantly nonamers, matched the reported HLA-A*11:01 motif, and
were found to bind to HLA-A*11:01 using a competitive binding
assay. Nonetheless, the relevance of peptides encoded by the
HIV-1 genome to disease is primarily derived from their func-
tional role as immune epitopes. Gamma interferon ELISPOT as-
say analysis in this study showed that elite controllers, viremic
controllers, noncontrollers, and ART-treated patients all re-
sponded to the ligands discovered here. Four longer Gag, Pol, and
Nef peptides of 10 to 17 amino acids in lengthwere highly reactive,
demonstrating that longer epitopes, irrespective of binding
affinity, are quite immunologically active. Among the 23 infected
individuals tested for reactivity with these 42 HIV-1 ligands, 19
people responded to Nef-QK10, 17 individuals responded to Nef-
VK17, and 14 people responded to Nef-KK11 (Fig. 4B and 5C). At
first glance, the responses observed within the major Gag hot spot
seem to contradict a length/reactivity trend, as only 2 donors re-
sponded to RK20 and 5 responded to AM14, while 9 responded to
the shorter SM10 version of this peptide. However, the median
strength of the response is reciprocal and fits the observation that
longer is stronger, whereby RK20 is more reactive than AM14,
which is more reactive than SM10.
In addition to observing clusters of HIV-1 ligands, it was quite
surprising to findmutant ligands of theHIV-1NL4-3 strain that was
used for infection. Cells within the bioreactor system employed
here were subjected to daily additions of clonal NL4-3, so one
might speculate that for amutation to arise it must provideHIV-1
with a substantial advantage in fitness to become established in an
NL4-3-rich culture. Alternatively, a virus-mediated alteration in
translation or RNA editing might have contributed to these mu-
tant HIV-1 ligands, although the same modification would need
to arise repeatedly within the system. Whatever the mechanism,
toggling amino acid substitutions arise within the ligands sampled
by HLA-A*11:01 in the absence of selective immune pressures.
Two additional elements of the study data merit discussion.
The first is the observation that HLA-A*11:01 preferentially sam-
ples newly synthesized viral ligands. This is illustrated by the Gag
ligands that span amino acids 361 to 384, a region containing two
cleavage sites for the HIV-1 protease (Fig. 2B). Briefly, a virion
matures into an infectious virus after it buds from the infected cell
and is then released. This transition requires the cleavage of the
Gag precursor protein (Pr55Gag) by the viral protease.Here, we see
that embedded within the 12 overlapping Gag ligands are the 2
cleavage sites that flank the p2 protein. This demonstrates that 10
of these 12 ligands can be derived only from nascent precursor
Gag proteins that arise following infection and not from infecting
mature viral particles, as has been described in some cases (37).
Furthermore, these 10 nascent Gag ligands all share the canonical
R/K C-terminal anchor preferred by HLA-A*11:01. The 2 ligands
that could be derived from either a mature or an immature Gag
protein, the p2 peptide AM14 and its shorter version, SM10, have
a noncanonical C-terminal methionine (M) anchor. These un-
usual anchors suggest that they may have been processed and
loaded via a differentmechanism.Whether or not a preference for
nascent ligand sampling applies to all viral proteins sampled by
HLA-A*11:01 or even to all class I HLA-presented HIV-1 ligands
will require further investigation.
The second notable observation is that which was not found in
this study. Three-fourths of theHIV-1 ligands previously reported
to be HLA-A*11:01 T cell epitopes were conspicuously absent
here. On one hand, a number of previously characterized HLA-
A*11:01 HIV-1 epitopes from Gag, Nef, and Pol were readily de-
tected by DLS and were T cell reactive, as reported here (Fig. 5C,
LANL ligands highlighted in green). On the other hand, the re-
maining 16 reportedHIVCTL epitopes were not apparent byDLS
and could not be specifically identified, despite our best efforts to
use MS/MS data from synthetic versions of these previously re-
ported HLA-A*11:01 ligands to provide a trail for tracking the
HIV T cell epitopes amid directly eluted ligands. One must con-
sider the possibility that CTLs directed toward these missing li-
gands would be unsuccessful in their mission of targeting HIV-1-
infected CD4 T cells. Alternative strains of HIV-1, CD4 T cell
lines, and allelic variants of HLAmust be tested to substantiate the
interpretation that numerous CTL-reactive epitopes are notmade
available by theHLAof infected T cells. It is intriguing to consider,
though, that particular HIV-1 peptide epitopes may serve as de-
coys by eliciting CTLs that cannot, in turn, target infected CD4T
cells due to epitope absence.
In summary, 42 HIV-1 genome-encoded ligands presented by
HLA-A*11:01 of HIV-1-infected cells were discovered by DLS.
Previously reported HIV-1 T cell epitopes were clearly identified
among the ligands eluted fromHLA-A*11:01, as were a consider-
able number of previously unreported epitopes.Many of the novel
HIV-1 ligands reported here are longer in length than previously
expected, spanning as many as 20 amino acids, yet they bind to
HLA-A*11:01 and stimulate T cell responses. A considerable
number of these length variants are located in overlapping bun-
dles of Nef and Gag epitopes, and the proteolytic cleavage sites
embedded in more than half of the reported Gag ligands suggest
that HLA-A*11:01 presents newly translated HIV-1 peptide
epitopes. Future studies will be needed to determine whether we
might have indeed sold ourselves too short in the mapping and
selection of CTL epitopes and whether other HLA share the HLA-
A*11:01 preference for nascent viral epitopes.
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